MedTrace Logo

Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis

NCT01570504 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 312

Last updated 2018-06-14

No results posted yet for this study

Summary

Ivermectin is currently the best drug to cure strongyloidiasis, but the "standard" single dose of 200 mcg/kg is probably not enough to guarantee cure. As strongyloidiasis can be fatal in immunosuppressed patients, it is mandatory to define the optimal dosage to eradicate the parasite.

Aim of this study is to define the most effective dose schedule of ivermectin to cure strongyloidiasis.

Conditions

  • Strongyloidiasis

Interventions

DRUG

Ivermectin

oral formulation

Sponsors & Collaborators

Principal Investigators

  • Zeno Bisoffi, MD, PhD · Centre for Tropical Diseases, Negrar (Verona), Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2018-06-08
Completion
2018-06-08

Countries

  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01570504 on ClinicalTrials.gov